. "98% bound to serum proteins, primarily serum albumin and to a lesser extent α1 acid glycoprotein"@en . . "approved"@en . . . " "@en . . "Nateglinide activity is dependent on the presence functioning \u03B2 cells and glucose. In contrast to sulfonylurea insulin secretatogogues, nateglinide has no effect on insulin release in the absence of glucose. Rather, it potentiates the effect of extracellular glucose on ATP-sensitive potassium channel and has little effect on insulin levels between meals and overnight. As such, nateglinide is more effective at reducing postprandial blood glucose levels than fasting blood glucose levels and requires a longer duration of therapy (approximately one month) before decreases in fasting blood glucose are observed. The insulinotropic effects of nateglinide are highest at intermediate glucose levels (3 to 10 mmol/L) and it does not increase insulin release already stimulated by high glucose concentrations (greater than 15 mmol/L). Nateglinide appears to be selective for pancreatic \u03B2 cells and does not appear to affect skeletal or cardiac muscle or thyroid tissue."@en . . . . . . . . . . . . . . "For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise."@en . . . . . . . "Michito Sumikawa, \"Methods for producing nateglinide B-type crystals.\" U.S. Patent US20030229249, issued December 11, 2003."@en . . . "Take upto 30 minutes before meals."@en . . . . "10 liters in healthy subjects"@en . . . "An overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms."@en . "105816-04-4"@en . . . . . . . . . . . "Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to \u03B2 cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those na\u00EFve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Nateglinide is extensively metabolized in the liver and excreted in urine (83%) and feces (10%). The major metabolites possess less activity than the parent compound. One minor metabolite, the isoprene, has the same potency as its parent compound. "@en . . . . . . . . . . . . . "1.5 hours"@en . . . . . . . "Urine (83%) and feces (10%)"@en . . "Nateglinide"@en . . . . . "Humans and other mammals"@en . . . "investigational"@en . " "@en . . . . "Rapidly absorbed following oral administration prior to a meal, absolute bioavailability is estimated to be approximately 73%. Peak plasma concentrations generally occur within 1 hour of oral administration. Onset of action is <20 minutes and the duration of action is approximately 4 hours. "@en .